OptimizeRx Corp Form 8-K February 22, 2017

SECURITIES AND EXCHANGE COMMISSION		
WASHINGTON, D.C. 20549		
FORM 8-K		
CURRENT REPORT		
PURSUANT TO SECTION 13 OR 15(d)	OF	
THE SECURITIES EXCHANGE ACT O	F 1934	
Date of Report (Date of earliest event reported	ed): February 22, 2017	
OptimizeRx Corporation (Exact name of registrant as specified in its c	harter)	
Nevada (State or other jurisdiction of incorporation)	000-53605	26-1265381
	(Commission File Number)	(I.R.S. Employer Identification No.)
400 Water Street, Suite 200, Rochester, MI (Address of principal executive offices)	48307 (Zip Code)	
Registrant's telephone number, including area code: 248.651.6568		

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

SECTION 2 – Financial Information

Item 2.02 Results of Operations and Financial Condition.

On February 22, 2017, we issued a press release announcing the details of our earnings conference call, to be held on Wednesday, March 8, 2017 at 4:30 p.m. ET.

The press release is furnished with this Current Report on Form 8-K as Exhibit 99.1. The information furnished under this Item 2.02 and Item 9.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any registration statement or other filing under the Securities Act of 1933, as amended, regardless of any general incorporation by reference language in such filing, except as shall be expressly set forth by specific reference in any such filing.

SECTION 9 – Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits

Exhibit No. Description

99.1 Press release, dated February 22, 2017

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

OptimizeRx Corporation

/s/ Doug Baker

Doug Baker Chief Financial Officer

Date: February 22, 2017